期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 26, 期 6, 页码 735-739出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2017.1323868
关键词
Amyloid; Alzheimer's; clinical trials; dimebon; monoclonal antibodies; secretase inhibitors
资金
- National Institute on Aging [P30 AG019610]
- Barrow Neurological Institute
- NATIONAL INSTITUTE ON AGING [P30AG019610] Funding Source: NIH RePORTER
Introduction: There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes.Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug. Data for these compounds were sought through a PubMed search and a clinicaltrials.gov search.Expert opinion: The obvious question to be posed is: Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate? This review summarizes the drugs that have failed during 2010-2015 and offers possible theories as to why they have failed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据